Trials / Completed
CompletedNCT00054886
Study of the Safety and Efficacy of SU-011,248 in Adult Patients With Advanced Kidney Cancer
Phase II Study Of Single-Agent SU011248 In The Second-Line Treatment Of Patients With Metastatic Renal Cell Carcinoma
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 63 (planned)
- Sponsor
- Pfizer · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The primary goal of the study is to evaluate the effectiveness and safety of SU-011,248 as a treatment for metastatic kidney cancer.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | SU-011,248 |
Timeline
- Start date
- 2003-01-01
- Completion
- 2004-08-01
- First posted
- 2003-02-13
- Last updated
- 2007-05-07
Locations
15 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT00054886. Inclusion in this directory is not an endorsement.